For many, this dramatic decline caught observers off guard. For example, in October 2020, the Nobel Prize in Chemistry validated the discovery of CRISPR genome editing and helped fuel a surge in the valuation of CRISPR biotech stocks. But those gains have long since evaporated. Among three prominent CRISPR-based drug developers, CRISPR Therapeutics shares have cratered 79% year-to-date, to $16.13 on Friday. During the same period, shares of Editas Medicine have dropped 39%, to $16.13, while Intellia Therapeutics shares have fallen 23%, to $91.41 . . .

Get GEN Edge Today!

See More on the Edge

Continue reading this article and more
with a GEN Edge subscription

Start Your 30-Day Free Trial Now

Log In Join GEN Edge

The post Top 5 Reasons behind the Biopharma Bear Market appeared first on GEN – Genetic Engineering and Biotechnology News.